Online inquiry

IVTScrip™ mRNA-Anti-PCSK9, LGT209(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10302MR)

This product GTTS-WQ10302MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets PCSK9 gene. The antibody can be applied in Heterozygous familial hypercholesterolemia (HeFH) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_174936.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 255738
UniProt ID Q8NBP7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PCSK9, LGT209(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ10302MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ320MR IVTScrip™ mRNA-Anti-IGF1R, 19D12(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 19D12
GTTS-WQ13089MR IVTScrip™ mRNA-Anti-MADCAM1, PF-00547659(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PF-00547659
GTTS-WQ5727MR IVTScrip™ mRNA-Anti-CEACAM5, CEA-IL-2v(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CEA-IL-2v
GTTS-WQ10589MR IVTScrip™ mRNA-Anti-ANGPT2, LY-3127804(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LY-3127804
GTTS-WQ1157MR IVTScrip™ mRNA-Anti-VEGFA, ABP 215(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABP 215
GTTS-WQ15937MR IVTScrip™ mRNA-Anti-Felcat NGF, ZTS-00084768(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ZTS-00084768
GTTS-WQ13356MR IVTScrip™ mRNA-Anti-LRRC15, PR-1498487(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PR-1498487
GTTS-WQ4115MR IVTScrip™ mRNA-Anti-ICAM1, BI-505(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BI-505
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW